Preoperative Systemic Therapy for Breast Cancer

Abhigna Kodali; Vijayakrishna K Gadi

doi:10.1016/j.suc.2022.08.017

Preoperative Systemic Therapy for Breast Cancer

Surg Clin North Am. 2023 Feb;103(1):201-217. doi: 10.1016/j.suc.2022.08.017. Epub 2022 Oct 18.

Authors

Abhigna Kodali¹, Vijayakrishna K Gadi²

Affiliations

¹ Division of Hematology and Oncology, Maimonides Cancer Center, 6300 Eight Avenue, Brooklyn, NY 11220, USA. Electronic address: akodali@maimonidesmed.org.
² Division of Hematology and Oncology, University of Illinois Chicago and Translational Oncology Program, University of Illinois Cancer Center, 818 South Wolcott Avenue, 410 SRH, Chicago, IL 60612, USA.

PMID: 36410351
DOI: 10.1016/j.suc.2022.08.017

Abstract

The indications for preoperative/neoadjuvant systemic therapy in breast cancer have changed over the past few years. In this article, the authors review the current data for use of neoadjuvant therapy in inoperable and operable settings. The evolution of various neoadjuvant regimens used in triple-negative breast cancer, human epidermal growth factor receptor 2 (HER2) overexpressing/gene-amplified (HER2+) tumors, and hormone receptor positive breast cancer is discussed as well as the role of neoadjuvant chemotherapy in tailoring adjuvant treatment.

Keywords: HER2 positive breast cancer; Hormone receptor–positive breast cancer; Neoadjuvant therapy; Preoperative therapy; TNBC.

Publication types

Review

MeSH terms

Humans
Immunotherapy
Neoadjuvant Therapy*
Triple Negative Breast Neoplasms* / drug therapy
Triple Negative Breast Neoplasms* / surgery